US Patent

US10596107 — Ophthalmic suspension composition

Method of Use · Assigned to Bausch and Lomb Inc · Expires 2036-12-23 · 11y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a formulation vehicle for an ophthalmic suspension that includes a suspending agent and a non-ionic cellulose derivative.

USPTO Abstract

A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D v90 <5 Î¼m and D v50 <1 Î¼m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Drugs covered by this patent

Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2764`	—	Lotemax

Patent Metadata

Patent number: US10596107
Jurisdiction: US
Classification: Method of Use
Expires: 2036-12-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Bausch and Lomb Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.